MedTrace Logo

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

NCT04753658 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2024-09-23

Study results available
· View outcomes & findings →

Summary

The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.

Conditions

Interventions

DRUG

lorlatinib

Oral

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-19
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • United States
  • Australia
  • New Zealand
  • Portugal
  • South Korea
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04753658 on ClinicalTrials.gov